Slide 1: Q3 2024 Results Conference Call and Webcast
Q3 2024 Results Conference Call and Webcast October 31, 2024 Nasdaq: ZYME | zymeworks.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary include “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchan
Slide 3: Q3 2024 Earnings Results Call Agenda
Q3 2024 Earnings Results Call Agenda Leone Patterson, MBA, CPA Paul Moore, Ph.D. Ken Galbraith EVP, CBO and CFO CSO Chair and CEO • Business Update • R&D Update • Q&A • Financial Update • Q&A • Q&A Making a Meaningful Difference 3
Slide 4: Leone Patterson, MBA, CPA
Leone Patterson, MBA, CPA EVP, CBO and CFO Making a Meaningful Difference 4
Slide 5: Recent Developments
Recent Developments Preclinical data on ZW251 demonstrating compelling preclinical activity in hepatocellular carcinoma model bearing a topoisomerase I inhibitor payload IND applications cleared Recognized revenue of $2.5m by the US FDA for ZW191 research milestone payment and ZW171 from GSK Aug Sep
Slide 6: Stock Repurchase Program
Stock Repurchase Program • On August 1, 2024, we adopted a stock repurchase program (the “Repurchase Program”), whereby the Company may repurchase up to $60.0M of the Company’s outstanding common stock, with an initial authorized phase of $30.0M. • As of September 30, 2024, we had completed the repu
Slide 7: Q3 2024 YTD Financial Results
Q3 2024YTD Financial Results • Revenue decreased in Q3 2024YTD primarily due to lower development support payments from Jazz partially offset by Q3 2024YTD Q3 2023YTD milestone revenue from BeiGene and GSK. In millions USD • R&D Expense decreased primarily due to a decrease in expenses for zanidatam
Slide 8: Projected Cash Runway Supports R&D Priorities into 2H 2027
Projected Cash Runway Supports R&D Priorities into 2H 2027 Current Financial Status: Potential sources to extend cash runway beyond 2H 2027: • Cash resources1 of approx. $375M (as of Sept 30, 2024) • Additional regulatory approval and commercial milestones for zanidatamab from Jazz and • Anticipated
Slide 9: Paul Moore, Ph.D.
Paul Moore, Ph.D. Chief Scientific Officer Making a Meaningful Difference 9
Slide 10: ZW220 Demonstrates Anti-tumor Efficacy in NaPi2b-expressing Models
ZW220 Demonstrates Anti-tumor Efficacy In NaPi2b-expressing Ovarian, Endometrial and NSCLC in vivo Models Ovarian Endometrial Lung CTG-0703 OC PDX UT5321 EC PDX H441 NSCLC CDX ZW220 was active at 6 mg/kg in a majority of ovarian, endometrial and NSCLC models tested NaPi2b IHC NaPi2b IHC NaPi2b IHC •
Slide 11: ZW220 Displays Bystander-Mediated Killing Activity
ZW220 Displays Bystander-Mediated Killing Activity NaPi2b expression heterogeneity ZW220 is highly active and demonstrates bystander killing in vitro, with significant size reduction of heterogeneous NaPi2b spheroids HCC-78, NaPi2b-high cell line, co-cultured with NaPi2b-negative carcinoma cell line
Slide 12: ZW220 is Well Tolerated in Preclinical Toxicology Models
ZW220 is Well Tolerated in Preclinical Toxicology Models Rat toxicology (non-GLP) Non-human primate (NHP) toxicology (non-GLP) 2-dose non-GLP Rat toxicology study ZW220, Q3Wx2 3-dose non-GLP NHP toxicology study ZW220*, Q3Wx3 Dose levels: Dose Dose levels: Dose 1 Dose 2 Dose 1 Dose 2 Dose 3 100 mg/k
Slide 13: ZW251 Demonstrates Robust in Vivo Anti-Tumor Activity in HCC Xenograft Models
ZW251 Demonstrates Robust in Vivo Anti-Tumor Activity in HCC Xenograft Models Dose Response Activity Representative HCC PDX Model Activity Breadth of Activity Breadth of ZW251 anti-tumor activity across all tested CDX/PDX models of HCC. Anti-tumor activity at 8 mg/kg was determined by %tumor growth
Slide 14: ZW251 Well Tolerated in Repeat Dose Non-Human Primate Toxicology Study
ZW251 Well Tolerated in Repeat Dose Non-Human Primate Toxicology Study and Exhibits Dose-Proportional Pharmacokinetics A B C (A) Study design of a repeat dose non-GLP toxicology study in cynomolgus monkeys performed to assess the tolerability and pharmacokinetic profile of ZW251. (B) Toxicology resu
Slide 15: ADC Designed to Simultaneously Enhance Efficacy and Tolerability
ADC Designed to Simultaneously Enhance Efficacy and Tolerability Efficacy Tolerability Payload Moderate potency should enable high protein dose and drive better tumor Moderate potency may limit damage where penetration and target engagement. conjugated drug accumulates in some Bystander activity and
Slide 16: ZW191 Global Phase 1 Study in FRα-Expressing Solid Tumors
ZW191 Global Phase 1 Study in FRα-Expressing Solid Tumors (NCT06555744) Open-label, FIH, dose-escalation study N= ~145 KEY ELIGIBILITY CRITERIA Part 2: Dose Expansion Part 1: Dose Escalation Part 2a: Dose Optimization Part 2b: Dose Expansion Inclusion criteria • Pathologically confirmed ovarian Ovar
Slide 17: ZW171 Clinical Development Progress
ZW171 Clinical Development Progress North America NA UK United Kingdom UK NA Europe SK South Korea SK North America South Korea EMA: European Medicines Agency; US FDA:U.S. Food and Drug Administration; MFDS: Ministry of Food and Drug Safety; MHRA: Medicines and Healthcare Products Regulatory Agency
Slide 18: Zymeworks R&D Day 2024: Thursday, December 12, 2024
Zymeworks R&D Day 2024: Thursday, December 12, 2024 Date: Thursday, December 12, 2024 Time: 7:30 am - 1:00 pm ET Location: Lotte Palace New York, 455 Madison Avenue at 50th Street, New York, NY 1002 About the Event: The event will be led by Dr. Paul Moore, Chief Scientific Officer and other members
Slide 19: Zymeworks: A Differentiated Product Pipeline
Zymeworks: A Differentiated Product Pipeline Built on Unique Capabilities in Antibody Engineering and Medicinal Chemistry Seeking to address unmet patient Focus on Gyn CA, Lung CA, & GI CA Pipeline Events needs in HER2+ GI Cancers • Anticipated nomination of Tri-TCE zanidatamab • ZW171 (Actively rec
Slide 20: Q&A
Q&A Ken Galbraith Chair & CEO Paul Moore, Ph.D. CSO Leone Patterson, MBA, CPA EVP, CBO and CFO Making a Meaningful Difference 20